The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance by Barbone, D et al.
The Bcl-2 repertoire of mesothelioma spheroids
underlies acquired apoptotic multicellular resistance
D Barbone*
,1,2, JA Ryan
3, N Kolhatkar
1,4, AD Chacko
2, DM Jablons
4, DJ Sugarbaker
5, R Bueno
5, AG Letai
3, LM Coussens
4,
DA Fennell
2 and VC Broaddus
1
Three-dimensional (3D) cultures are a valuable platform to study acquired multicellular apoptotic resistance of cancer. We used
spheroids of cell lines and actual tumor to study resistance to the proteasome inhibitor bortezomib in mesothelioma, a highly
chemoresistant tumor. Spheroids from mesothelioma cell lines acquired resistance to bortezomib by failing to upregulate Noxa,
a pro-apoptotic sensitizer BH3-only protein that acts by displacing Bim, a pro-apoptotic Bax/Bak-activator protein. Surprisingly,
despite their resistance, spheroids also upregulated Bim and thereby acquired sensitivity to ABT-737, an inhibitor of anti-
apoptoticBcl-2molecules.AnalysisusingBH3proﬁlingconﬁrmedthatspheroidsacquiredadependenceonanti-apoptoticBcl-2
proteins and were ‘primed for death’. We then studied spheroids grown from actual mesothelioma. ABT-737 was active in
spheroids grown from those tumors (5/7, B70%) with elevated levels of Bim. Using immunocytochemistry of tissue microarrays
of 48 mesotheliomas, we found that most (33, 69%) expressed elevated Bim. In conclusion, mesothelioma cells in 3D alter the
expression of Bcl-2 molecules, thereby acquiring both apoptotic resistance and sensitivity to Bcl-2 blockade. Mesothelioma
tumors ex vivo also show sensitivity to Bcl-2 blockade that may depend on Bim, which is frequently elevated in mesothelioma.
Therefore, mesothelioma, a highly resistant tumor, may have an intrinsic sensitivity to Bcl-2 blockade that can be exploited
therapeutically.
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Resistance to apoptosis may underlie the chemoresistance of
tumors.
1,2 Apoptotic resistance and chemoresistance, how-
ever, may not be fully reﬂected in two-dimensional (2D) cell
cultures (monolayers). Indeed, when cancer cells are grown
as three-dimensional (3D) spheroids, they acquire multi-
cellular resistance thatmimicsthe chemoresistance observed
in vivo and can effectively recapitulate some of the complexity
of solid tumors.
3–5
Understanding multicellular resistance may provide key
insights into effective therapies for recalcitrant solid tumors
such as human malignant mesothelioma,
6 which usually
presents at a late stage as a thick tumor mass.
7 At this time,
few effective therapeutic options are available for meso-
thelioma patients and survival remains poor. Our group
8 and
others
9 have found that mesothelioma spheroids acquire
multicellular resistance to a variety of treatments.
8,9 We
decided to focus on resistance to bortezomib (PS-341,
Velcade), an agent that has shown promise in pre-clinical
studies of mesothelioma
10,11 and is now being evaluated in
clinical trials. Although it is not yet known whether meso-
thelioma will exhibit resistance to bortezomib, bortezomib
resistance, while rare in hematologic cancers,
12 has been a
common problem in solid tumors.
13
Bortezomib, a proteasome inhibitor, is thought to induce
apoptosis via the alteration of expression of Bcl-2 proteins.
14
Thus, resistance to bortezomib may also manifest itself in
changes in the balance of the pro- and anti-apoptotic Bcl-2
molecules.If so,new experimentalapproaches,suchasBcl-2
homology domain 3 (BH3)-proﬁling, may be used to uncover
the anti-apoptotic barriers mediating resistance. With BH3-
proﬁling, the cellular dependence on anti-apoptotic proteins
can be decoded based on mitochondrial sensitivity to a panel
of BH3 peptides.
15 In addition, using mechanistic approaches
such as these, it has been seen that anti-apoptotic resistance
mechanisms may coexist with a high level of pro-apoptotic
potential, a situation termed ‘primed for death’. Tumors
identiﬁed as ‘primed for death’ may respond to inhibition of
the anti-apoptotic defenses with small molecules such as
ABT-737, an inhibitor of Bcl-2/XL/w. Probing of the anti-
apoptoticstrategiesof3Dspheroidsmayrevealvulnerabilities
that can be sought in tumors as well.
Here, we have investigated the multicellular resistance and
the apoptotic priming that develops in mesothelioma cells
grown in 3D spheroids. By using Bcl-2 inhibitors and BH3-
proﬁling, we have probed the anti-apoptotic defenses of
multicellular spheroids and also of human mesothelioma
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presents for the ﬁrst time key insights into the apoptotic
repertoire of 3D spheroids and proposes ways to detect the
pro-apoptotic potential within mesothelioma and to exploit it
therapeutically.
Results
Mesothelioma cells acquire resistance to bortezomib
when grown as 3D spheroids. We ﬁrst studied two
mesothelioma cell lines, M28 and REN, previously reported
to be sensitive to bortezomib-induced apoptosis
10 and known
to form spheroids.
8 Monolayers and spheroids were treated
with increasing doses of bortezomib (1–100nM) for 48h.
Monolayers displayed an IC50
(48h) of approximately 18nM
(M28) and 9nM (REN), whereas spheroids exhibited
resistance, with an approximate IC50
(48h) of 100nM (M28
and REN) (Figure 1a).
Resistance was not due to differences of proteasome
activity at baseline or after bortezomib. We found that the
proteasomal chymotryptic activity of monolayers and spher-
oids of REN cells was equal at baseline and equally inhibited
following exposure to bortezomib or to another proteasome
inhibitor, MG-132, for 4h (Figure 1b).
Resistance was not a function of high cell density, as has
been proposed.
16 We found that completely conﬂuent
monolayers did not acquire resistance to bortezomib
(Figure 1c), but were as responsive to bortezomib as the
subconﬂuent monolayers.
In spheroids, pro-apoptotic Noxa is not upregulated by
bortezomib whereas Bim is high. The proteasome
recycles 480% of the total protein content of cells
17 and
thereby mediates the activity of key cellular functions such as
apoptosis. Bortezomib-induced apoptosis has been
attributed to the accumulation of the pro-apoptotic BH3-
only protein Bim and the induction of other pro-apoptotic
sensitizers such as Noxa.
14,18–20 We asked whether
bortezomib might alter these apoptotic triggers differently in
spheroids and, if so, whether such differences might underlie
spheroids’ acquired multicellular resistance.
Using immunoblotting, we analyzed the expression of key
Bcl-2 proteins in monolayers and spheroids before and after
treatment with bortezomib (Figure 2). In monolayers exposed
to bortezomib, Noxa was strongly upregulated. In spheroids
exposed to bortezomib, however, Noxa failed to increase.
In addition, spheroids upregulated Bim expression at
baseline and following bortezomib (Figure 2). Intriguingly,
spheroids, despite their increased apoptotic resistance,
expressed more pro-apoptotic Bim than did monolayers.
Because Noxa functions indirectly by displacing Bim from
anti-apoptoticMcl-1,weaskedwhetheradditionofNoxatothe
spheroids could restore apoptotic sensitivity.
A Noxa peptide reduces multicellular resistance
acquired by spheroids. To conﬁrm that Noxa contributed
to the apoptosis induced by bortezomib in the monolayers,
we reduced Noxa expression by siRNA. Silencing
successfully reduced bortezomib-induced Noxa
upregulation, without alteration of other Bcl-2 molecules,
Mcl-1 or Bim (Figure 3a). The reduction in Noxa signiﬁcantly
reduced apoptosis in monolayers following bortezomib,
suggesting an important role for Noxa in mediating
bortezomib-induced apoptosis (Figure 3a). We then
attempted to restore Noxa in spheroids using a Noxa
BH3
peptide bound to 8 arginine residues (R8-Noxa
BH3), a
modiﬁcation that aids diffusion of the peptide across cell
membranes.
21,22 Although an R8 control peptide had no
activity, R8-Noxa
BH3 enhanced the apoptotic response of the
spheroids, thereby signiﬁcantly reducing the multicellular
resistance of spheroids to bortezomib (Figure 3b). In
addition, R8-Noxa
BH3 alone induced apoptosis in REN
spheroids. To determine whether R8-Noxa
BH3 peptide had
off-target effects, we ablated Mcl-1 by siRNA. Because Noxa
activity requires Mcl-1, we would expect R8-Noxa
BH3 to have
no activity in the absence of Mcl-1. Without Mcl-1,
R8-Noxa
BH3 lost all apoptotic activity indicating that, at
Figure 1 Spheroids grown from mesothelioma cell lines acquire multicellular
resistancetobortezomib.(a)M28andRENmonolayersandspheroidsweretreated
with bortezomib 1, 5,10, 25 or 100nM for 48h. Apoptosis was measured in
Hoechst-stained cells; cells with signs of nuclear condensation were considered
apoptotic. Spheroids grown from both cell lines acquired a marked multicellular
resistance to bortezomib even at the highest concentrations. (*Po0.05 spheroids
compared with monolayers, n¼3). (b) REN monolayers and spheroids were
treated with bortezomib (100nM) or MG-132 (10mM), a potent proteasome
inhibitor, for 4h before cells were lysed and analyzed for proteasomal activity.
Monolayersandspheroidsshowedsimilarproteasomalactivityatbaselineandwere
both equally inhibited by bortezomib or MG-132 after 4h. (*Po0.05 compared with
untreated control, n¼3). (c) M28 and REN monolayers at standard conﬂuence
(70%), completely conﬂuent monolayers (obtained by plating twice the number of
cells to achieve at least 100% conﬂuence) and spheroids were treated with
bortezomib (25 or 100nM). Completely conﬂuent monolayers showed an apoptotic
response comparable to monolayers and did not acquire multicellular resistance.
(*Po0.05 spheroids compared with monolayers and conﬂuent monolayers, n¼3)
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Cell Death and Diseaseleast in these cells at the concentrations used, Noxa peptide
activity was speciﬁcally targeted to Mcl-1 (Supplementary
Figure 1).
The activity of the Noxa peptide suggested that the lack of
Noxaupregulation inspheroids contributed tothe multicellular
resistance to bortezomib. Nevertheless, Noxa, as a BH3-only
sensitizer, depends on the presence of a pro-apoptotic
Bax/Bak-activator such as Bim. The high expression of Bim
in the spheroids suggested that the spheroids were primed for
apoptotic death and thus vulnerable to other approaches
designed to release Bim.
ABT-737 reduces multicellular resistance of
spheroids. We asked whether ABT-737, a small molecule
that inhibits Bcl-2/XL/w, would be effective in spheroids by
unmasking the pro-apoptotic potential revealed by the
R8-Noxa
BH3 peptide. Indeed ABT-737 (1mM) increased the
apoptotic response to bortezomib of spheroids as well as of
monolayers and reversed the multicellular resistance of
spheroids (Figure 4). Moreover, ABT-737 alone induced
apoptosis of both M28 and REN spheroids, conﬁrming that
spheroids are ‘primed for death’
15 and dependent on their
anti-apoptotic defenses for survival. To conﬁrm the role of
Bim in the activity of ABT-737, we reduced Bim expression
using siRNA. Knockdown of Bim abolished the ability of
ABT-737 by itself to induce apoptosis in spheroids and
signiﬁcantly reduced its ability to enhance bortezomib-
induced apoptosis (Figure 5a).
Unlike Bcl-2/XL/w, Mcl-1 is not inhibited by ABT-737 and is
known to mediate resistance to ABT-737.
23,24 We ablated
Mcl-1 using siRNA to determine its contribution to resistance
in spheroids. Ablation of Mcl-1 increased the apoptotic
responses to ABT-737 and to bortezomib (Figure 5b). In fact,
inhibition of both Bcl-2/XL/w (by ABT-737) and Mcl-1 (by
siRNA)increasedtheapoptosisinM28andRENspheroids,to
100 and 65% of total cells, respectively, even in the absence
of bortezomib.
Figure 3 A Noxa peptide sensitizes spheroids to bortezomib-induced
apoptosis. (a) Noxa was silenced in REN cells and, 24h later, cells were plated
as monolayers and treated with bortezomib (25nM). After 4h, cells were collected
and lysed to verify the efﬁcacy of Noxa siRNA (see immunoblot). No changes in
other Bcl-2 proteins, Mcl-1 and Bim, were detected upon Noxa silencing, with or
withoutbortezomib.After24h,Hoechst-stainedcellswerecountedforthepresence
of apoptosis. Noxa siRNA signiﬁcantly reduced the apoptosis induced by
bortezomib. (*Po0.05, n¼3). (b) M28 and REN monolayers and spheroids were
treatedwithbortezomib(25nM),acell-permeableR8-Noxa
BH3peptide(50mM)ora
control R8 peptide (50mM), either alone or in combination, for 24h. R8-Noxa
BH3,
but not the R8 peptide, eliminated the acquired multicellular resistance of spheroids
to bortezomib without affecting monolayers. Interestingly, REN spheroids, but not
M28, were sensitive to R8-Noxa
BH3 alone. (*Po0.05 compared with untreated and
R8 control;
þþPo0.05 spheroids versus monolayers, n¼3)
Figure 2 Spheroids fail to upregulate Noxa after bortezomib but have a high
expression of Bim. M28 and REN monolayers and spheroids were treated with
bortezomib(25or100nM)for4or24h.Wholecelllysates(50mg)wereresolvedon
SDS-PAGE and immunoblotted for a panel of pro-/anti-apoptotic Bcl-2 proteins.
BothM28andREN monolayersupregulated Noxaafterbortezomib(25nM)at 24h.
(Owingtothehighdegreeofapoptosis,monolayerstreatedwith100nMbortezomib
at 24h were not collected.) Spheroids, however, failed to upregulate Noxa, even
after bortezomib 100nM at 24h. Interestingly, at baseline and during exposure to
bortezomib, spheroids expressed more Bim protein than monolayers. (Represen-
tative of three experiments)
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Cell Death and DiseaseABT-737 has been shown in some settings to alter levels of
Bcl-2 proteins,
25–27 including Mcl-1. To address this issue, we
grew REN cells as monolayers and spheroids and exposed
them to ABT-737 alone or to ABT-737 together with
bortezomib for 6h. During that time, selected to avoid the
changes induced by apoptosis, we found no signiﬁcant
change in the levels of two Bcl-2 proteins, Mcl-1 and Bim
(Supplementary Figure 2).
To determine whether ABT-737 or bortezomib acts on the
benign counterpart of mesothelioma, we studied normal
mesothelialcellsobtainedfrombenignhumanascites.Because
benign mesothelial cells in vivo exist as single cell monolayer
and in vitro do not form spheroids as readily as do malignant
cells, we studied them as monolayers. Normal mesothelial cells
did not undergo apoptosis following bortezomib, ABT-737 alone
or bortezomib plus ABT-737 (Supplementary Figure 3A). The
normal cells also did not express Bim, even following
bortezomib treatment for 6h (Supplementary Figure 3B).
Spheroids are ‘primed for death’. Mesothelioma cells in
3D spheroids thus appeared to acquire apoptotic resistance
along with an underlying sensitivity to apoptosis. We used
BH3-proﬁling to conﬁrm these ﬁndings in four cell lines (two
epithelioid lines, M28 and REN and two sarcomatous lines,
SARC and VAMT). For these studies, cells from monolayers
and spheroids were disaggregated identically to single cells
for ﬂow cytometry and probed with a panel of BH3 peptides
or small molecules such as ABT-737 for the loss of
mitochondrial potential indicative of apoptosis.
15
Cells derived from monolayers and spheroids were
equally sensitive to the Bim BH3 peptide, conﬁrming an equal
ability to activate the apoptotic program (Figure 6). However,
compared with cells from monolayers, cells from spheroids
were more sensitive to sensitizer BH3-only molecules,
Bad and Hrk, targeting Bcl-2 and Bcl-XL, respectively. In
addition, cells from spheroids were conﬁrmed to be more
sensitive to ABT-737, which had no effect on the cells from
monolayers.
Because cells from spheroids of the two additional
mesothelioma cell lines, VAMT and SARC, were found to be
sensitive to pro-apoptotic sensitizers by BH3-proﬁling, we
anticipated that they would also show sensitivity to BH3-only
sensitizers when tested in cell culture. Indeed, spheroids of
both cell lines were sensitive to ABT-737- and R8-Noxa
BH3-
induced apoptosis, even in the absence of bortezomib
(Figure 7a). When spheroids from all four cell lines were
compared, the M28 spheroids appeared to have less
sensitivity, with no response to R8-Noxa
BH3 given alone
(see also Figure 3b). We then conﬁrmed that the expression
levels of Bim increased in each cell line when grown as
spheroids. Of interest, the increase in Bim levels as estimated
by the ratio of densitometry values was less in M28 (1.9-fold
increase) when compared with the more sensitive lines (3.2–
4.5-fold increase) (Figure 7b and Supplementary Figure 4)
ABT-737 has activity against human mesothelioma
grown as TFS. The sensitivity of multicellular spheroids to
Bcl-2 blockade with ABT-737 raised the intriguing possibility
that human mesothelioma tumor cells in their 3D
environment might also be sensitive. Using a human tumor
Figure 4 ABT-737 eliminates multicellular resistance to bortezomib. M28 and
RENmonolayersandspheroidsweretreatedwithbortezomib(25nM)andABT-737
(1mM), either alone or in combination, for 24h. ABT-737 eliminated the acquired
multicellular resistance of spheroids to bortezomib. Interestingly, when given alone,
ABT-737 was able to induce apoptosis in spheroids but not in monolayers.
(*Po0.05 compared with bortezomib alone;
þþPo0.05 spheroids versus
monolayers, n¼3)
Figure 5 ABT-737 sensitization of spheroids to bortezomib is dependent on
Bim and aided by ablation of Mcl-1. (a) Bim was ablated in M28 and REN cells and,
24h later, cells were plated to generate monolayers and spheroids, exposed to
bortezomib 25nM and/or ABT-737 1mM for 24h and lysed and probed for Bim at
72h after siRNA (see immunoblot insert), the time when cells were counted for the
presence of apoptosis. The absence of Bim in spheroids completely abolished the
apoptotic effect of ABT-737 when given alone and signiﬁcantly reduced the effect
when given with bortezomib. (*Po0.05 compared with control siRNA,
þþPo0.05
spheroids versus monolayers, n¼3). (b) Mcl-1 was ablated, as performed for Bim
above (see immunoblot insert). The absence of Mcl-1 reduced the acquired
multicellular resistance of spheroids to bortezomib. The absence of Mcl-1 also
increased the apoptotic response to ABT-737 when given alone or in combination
with bortezomib. (*Po0.05 compared with control siRNA,
þþPo0.05 spheroids
versus monolayers, n¼3)
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Cell Death and Diseasefragment model we previously developed for ex vivo studies,
5
we tested spheroids grown from seven mesothelioma tumors
for responsiveness to ABT-737. In tumor fragments from ﬁve
of the tumors, ABT-737 did sensitize the mesothelioma cells
to bortezomib-induced apoptosis (Figures 8a and b). In two
cases, there was no response to ABT-737 (o5% apoptosis),
either when ABT-737 was given alone or together with
bortezomib. We then asked whether the level of Bim
expression could explain the different responses to
ABT-737 in these tumors. Using immunohistochemistry of a
tissue microarray (TMA) comprising the original tumor
samples from which the TFS were derived, we found that
the responsive tumors showed high Bim expression
compared with normal pleura, whereas the unresponsive
tumors expressed Bim at low or undetectable levels,
comparable to normal pleura (Figure 8c). The possibility
that Bim could represent a predictive biomarker for ABT-737
activity in mesothelioma prompted us to investigate the
frequency of Bim overexpression in mesothelioma tumors.
Using immunohistochemistry of 48 mesothelioma samples
and 5 normal pleural samples included on a tumor TMA and
assessed using an image analysis system, we found that
33 (69%) of mesothelioma tumors expressed Bim at levels
higher than in the normal tissues. Elevated Bim expression
was found in most tumors of the epithelioid (20 of 22) and
mixed subtype (12 out of 21) but was uncommon in the
sarcomatous subtype (only 1 of 5).
Figure 7 Apoptotic priming of spheroids increases with elevated Bim
expression. (a) Spheroids grown from M28, VAMT, REN and SARC cell lines
were treated with R8-Noxa
BH3 (50mM), ABT-737 (1mM), bortezomib (25nM) or
their combination for 24h. Whereas R8-Noxa
BH3 alone failed to induce apoptosis in
M28 spheroids, ABT-737 alone induced apoptosis in the spheroids generated from
all four cell lines. Nevertheless, when given with bortezomib, either R8-Noxa
BH3 or
ABT-737 was effective in increasing apoptosis of spheroids. (*Po0.05 compared
with untreated spheroids, **Po0.05 compared with bortezomib alone, n¼3).
(b) Immunoblot analysis of Bim expression in M28, REN, SARC and VAMT
monolayers and spheroids with densitometry shown for Bim, standardized for
a-tubulin expression. Immunoblot and densitometry values are representative of
three separate experiments. In all four cell lines, spheroids expressed increased
Bim levels. Compared with monolayers, spheroids of M28 displayed a 1.9-fold
increase inBimlevels whereasspheroidsof REN, SARCandVAMTshoweda 4.5-,
3.2- and 4.0-fold, increase, respectively
Figure 6 Spheroids are ‘primed for death’. BH3-proﬁling was performed on
cells disaggregated from monolayers and spheroids grown from M28, REN, SARC
andVAMTcells.Thecellsweregentlypermeabilizedasdescribed
39andexposedto
BH3 peptides (100mM) for 90min before JC1 was added for 30min and
depolarization measured as a percentage of the total. Cells from spheroids and
monolayers were equally depolarized by Bim
BH3, the positive control, conﬁrming a
functioning apoptoticapparatus. However,cells disaggregatedfromspheroidswere
more sensitive to Bad
BH3, Hrk
BH3 and ABT-737 than cells from monolayers,
conﬁrming that cells in 3D acquired apoptotic priming. Cells showed no response to
an ABT-737 inactive enantiomer, used as negative control. (*Po0.05 compared
with monolayers, n¼3)
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Understanding how cancer cells attain chemoresistance can
provide clues for designing new therapeutic strategies.
Because cancer cells in 3D cultures acquire a multicellular
resistance that resembles the chemoresistance seen in solid
tumors in vivo, 3D models may be a useful platform for
investigatingnoveltherapeuticapproaches.Inthisstudy,asin
previous studies in our laboratory, we investigated resistance
mechanisms using 3D models generated from cell lines that
we then tested for relevance in tumor grown ex vivo.
8,28 We
were particularly interested in applying this approach to
Figure 8 ABT-737 increases activity of bortezomib against mesothelioma cells in spheroids derived from tumors with high expression of Bim. (a) TFS generated from
seven tumors were treated with bortezomib (50nM), ABT-737 (2.5mM) or their combination for 24h. In the responsive tumors (n¼5) (shown), ABT-737 increased apoptosis
when giventogether with bortezomib. In unresponsivetumors (n¼2) (notshown), ABT-737 with or without bortezomib hadno effect (apoptosiso5%), (*Po0.05 compared
with no treatment, bortezomib alone or ABT-737 alone, n¼5). (b) Confocal images representative of the responsive tumor fragment spheroids treated with bortezomib
(50nM)withorwithoutABT-737(2.5mM)for24h.Pan-cytokeratin(red)wasusedtoidentifymesotheliomacellswithinthespheroidsandcleavedcaspase-3(green)toidentify
apoptosis. The merged color (yellow) identiﬁes apoptotic mesothelioma cells. The mesothelioma cells are resistant to ABT-737 alone (not shown) and to bortezomib alone.
The addition of ABT-737 to bortezomib, however, effectively increased apoptosis of the human mesothelioma cells. (c) Using a TMA generated with tissue from the original
seven tumors tested for apoptosis along with normal pleural tissue as control, Bim expression was determined by immunohistochemistry and quantiﬁed using an imaging
analysis system (ScanscopeXT, Aperio). Every sample was represented three times on the slide. Normal pleura and the two tumors not responsive to ABT-737 and
bortezomibshowedcomparable,very lowamountsof Bim.Conversely,theresponsivetumorsshowedstrong Bimstaining. Intensityof stainingwasexpressedaspercentage
compared with normal pleura. (*Po0.05 compared with normal and non-responsive)
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Cell Death and Diseasebortezomib, a therapy that has shown less efﬁcacy in solid
tumors than in non-solid tumors such as multiple myeloma,
perhaps because of resistance mechanisms seen only in 3D.
Although 2D models have been used to elucidate resistance
to bortezomib,
29 here we show for the ﬁrst time the additional
multicellular resistance mechanisms that develop in 3D.
Compared with the same cells in 2D, mesothelioma cells in
3Dexpressa differentbalanceofBcl-2pro-andanti-apoptotic
molecules and acquire a dual nature: on the one hand, they
become resistant to bortezomib; on the other hand, they
become dependent on anti-apoptotic Bcl-2 defenses and
therefore sensitive if the anti-apoptotic mechanisms are
neutralized. In the ex vivo human mesothelioma tumor model,
we found that blockade of the Bcl-2 anti-apoptotic molecules
enhanced the apoptotic response to bortezomib, at least in
tumors with overexpression of the pro-apoptotic BH3-only
molecule Bim. The response of the in vitro and ex vivo models
to inhibition of anti-apoptotic Bcl-2 members supports a new,
clinically relevant approach to this highly chemoresistant
tumor.
Mesothelioma cells in 3D acquired a resistance to bortezo-
mib that was initially identiﬁed by an inability to upregulate
Noxa, the pro-apoptotic BH3-only molecule that interacts with
Mcl-1 to release Bim.
30 In many systems, Noxa has been
showntomediatebortezomibactivity,
31–33aroleweconﬁrmed
in the mesothelioma monolayers. In spheroids, the addition of
a R8-Noxa
BH3peptidewasabletorestorebortezomib-induced
apoptosis to the same level as in the monolayers, suggesting
that the lack of Noxa upregulation contributed to the
bortezomib resistance in 3D. Because Noxa acts indirectly
by releasing Bim, we suspected that the effect of Noxa
depended on Bim and, as expected, the ablation of Bim
decreased theactivityofNoxa.However,we were surprisedat
the high level of Bim in the 3D spheroids, especially given their
chemoresistance. It suggested that the Bim was sequestered
and held in check by anti-apoptotic buffering and that, despite
apoptotic resistance, spheroids would be poised for apoptosis
if the Bim could be released. Indeed, the small molecule, ABT-
737, an inhibitor of Bcl-2/XL/w, was able to undermine the
bortezomib resistance of spheroids and, in some cell lines, to
induce apoptosis in spheroids by itself. In fact, when used as
single agents in the resistant spheroids, ABT-737 was more
effective than bortezomib.
By BH3-proﬁling, we conﬁrmed that the cells disaggregated
from the spheroids had acquired sensitivity to ABT-737 and to
peptides that displace Bim from Bcl-2 and Bcl-XL. Of interest,
the apoptotic priming was acquired as the malignant cells
moved to 3D, a feature that has not previously been
described. Analogous to what has been proposed for cancer
in general, spheroids acquired resistance to apoptosis along
with a latent pro-apoptotic potential that could be harnessed
therapeutically.
34
Mcl-1 can confer resistance to ABT-737 as well as to
bortezomib,
31–33 and can be a major resistance factor in 3D
spheroids, as we have previously shown in lung cancer.
35
Interestingly, in our studies in mesothelioma, the presence of
Mcl-1 did not prevent the response to ABT-737 although the
reduction of Mcl-1 (by R8-Noxa
BH3 or by Mcl-1 siRNA) did
increase the response to ABT-737, as has been previously
shown.
23 Thus, Mcl-1 appeared to blunt, but not block, the
activity of ABT-737 and the combined inactivation of both
Mcl-1 and the Bcl-2/XL/w was more effective than inhibition
of either one alone. Mcl-1 also appeared to have a smaller
role when the increase in Bim levels was lower. For example,
R8-Noxa
BH3 was less effective than ABT-737 in the cell line
with the lowest increase in Bim (M28). Therefore, we
speculate that Bim may be preferentially sequestered by
Bcl-2/XL/w, as has been described,
36 with additional buffering
by Mcl-1 as Bim increases. Nonetheless, Mcl-1 represents
a potential barrier to the use of ABT-737 clinically. Thus,
the effectiveness of ABT-737 in combination with bortezomib
or other therapies may be enhanced by agents that reduce
Mcl-1.
23,25,26
Why Bim increases in the 3D spheroids is not yet known;
nonetheless, the ﬁnding that Bim increases in mesothelioma
cells in 3D represents a unique and potentially important
observation. Bim was essential for the response to ABT-737,
asdemonstratedbytheBimsiRNAexperiments,andthelevel
of Bim correlated with sensitivity to ABT-737 in the multi-
cellular spheroids and in the tumor fragments. Bim may thus
be a useful predictive biomarker for the response of
mesothelioma to ABT-737 together with bortezomib. Almost
70% of mesotheliomas were found to express Bim at levels
higher than in normal tissue. Interestingly, Bim overexpres-
sion was frequent in the more chemosensitive subtype
(epithelioid, 90%) and uncommon in the more chemoresistant
subtype (sarcomatoid, 20%). Unleashing the pro-apoptotic
molecule Bim using small molecule inhibitors such as
ABT-737 may enhance the effectiveness of current chemo-
therapy in this recalcitrant tumor.
TFS were developed to investigate therapeutic
approaches in a clinically relevant ex vivo setting.
5 When
tested in TFS, ABT-737 was also effective, but only in
spheroids derived from tumors with a high expression of Bim.
Thus, by virtue of studies in these complementary 3D models,
wehaveidentiﬁedapotentialtherapy,ABT-737,andidentiﬁed
a possible biomarker for predicting response to ABT-737 in
this tumor, Bim. Further studies will be necessary to conﬁrm
the validity of these predictions. Nonetheless, we think that
agents able to upregulate Bim, such as vorinostat,
37 could be
potent adjuncts to current chemotherapies.
There are potential clinical beneﬁts to targeting tumors at
the level of their anti-apoptotic defenses. Most targeted
therapies have focused on impairing signaling pathways on
which cancers depend for survival.
38 However, the efﬁcacy of
these approaches may be impaired by intracellular signaling
redundancy, crosstalk, adaptation and differing levels of
activating/silencing mutations. Direct inhibitors of anti-apop-
totic defenses could bypass the need to inhibit multiple
pathways by moving to a distal level at which multiple signals
are integrated. Our data suggest that such an approach may
be effective in the different mesothelioma subtypes, against a
variety of apoptotic therapies, and without injury to normal
tissues.
In sum, using 3D culture models, we have shown that
multicellular resistance to bortezomib is mediated by altera-
tionsinthe Bcl-2repertoire,whichprovidesa druggabletarget
speciﬁc to the malignant cells. Inhibition of the anti-apoptotic
buffers in association with chemotherapy represents a
promising strategy for the treatment of mesothelioma.
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Cell cultures and reagents. The human mesothelioma cell lines M28, REN,
VAMT and SARC were cultured in DMEM supplemented with 10% FBS and 100IU/ml
penicillin–streptomycin in a 371C humidiﬁed incubator with 5% CO2 (full DMEM).
Primary human mesothelial cells were cultured from ascites ﬂuid from patients without
infection or malignancy according to a protocol approved by the UCSF Committee on
Human Research. TFS were generated as previously described
28. Tumor samples
were obtained from extrapleural pneumonectomy (EPP) or pleurectomy procedures
performed by DJS and RB at Brigham and Women’s Hospital in Boston, MA, USA.
R8-Noxa
BH3 (RRRRRRRR-EVECATQLRRFGDKLNFRQKL) and R8 (RRRRRRRR)
peptides were from Genscript (Piscataway, NJ, USA). Bortezomib (Velcade) was
fromMillenniumPharmaceuticals(Cambridge,MA,USA).ABT-737wasgenerously
provided from Abbott Pharmaceuticals (Abbott Park, IL, USA).
Generation and treatment of spheroids
Multicellular spheroids. Multicellular spheroids were generated in non-
adsorbent round-bottomed 96-well plates. The 96-well plates were coated with a
1:24 dilution of polyHEMA (120mg/ml) (#P3932, Sigma-Aldrich, St. Louis, MO,
USA) in 95% ethanol and dried at 371C for 48h. Before use, plates were sterilized
by UV light for 30min. For generation of multicellular spheroids, 10000 cells were
added into each well of polyHEMA-coated 96-well plate. The plates were brieﬂy
spunfor5minat800r.p.m.andthenplacedina371Chumidiﬁedincubatorwith5%
CO2for24h.Forgenerationofmonolayers,180000cellswereaddedintoeachwell
of six-well plates.
Tumor fragment spheroids. TFS were grown from seven tumor samples
obtained from surgical resection performed at the Brigham and Women’s Hospital
(Boston, MA, USA). A part of the tumor was ﬁxed in 10% formalin (Fisher Scientiﬁc,
Fair Lawn, NJ, USA) and embedded in parafﬁn. For spheroid culture, tumor tissue
was diced ﬁnely with scalpels to pieces smaller than 1mm in diameter that were
suspendedin mediumin 10-cm plates coated with 0.8% agar (Agar Noble, #A5431,
Sigma-Aldrich) in full DMEM. The volume of overlay media was 15ml, and half the
volume of the overlay media was changed twice a week. The agar-coated plates
were regularly observed using an inverted phase microscope during the incubation
period, up to 4 weeks. Spheroids were collected at different time points, treated as
described in ﬁgure legends, ﬁxed in 10% formalin and embedded in parafﬁn for
immunostaining.
Treatment. Before treatment, 18 multicellular spheroids or 20–30 TFS were
transferred to each well of a polyHEMA-coated 24-well plate to match the numbers
of cells plated as monolayers (180000 cells per well). The spheroids and
monolayers were treated with apoptotic agents in full DMEM with or without
inhibitors (and the appropriate DMSO vehicle control) for 24h.
Immunoblotting. After treatment, monolayers and spheroids were lysed in
boiling lysis buffer (2.5% SDS, Tris-HCl 250mM pH 7.4). The concentration of total
protein was evaluated with a colorimetric assay (DC protein assay from Bio-Rad,
Hercules, CA, USA). In all, 50mg of cell lysates were loaded in reducing conditions
(0.2M Tris, pH 6.8, 5% SDS, 3% glycerol, 0.01% bromophenol blue and 200mM
DTT). After separation in SDS-PAGE (5 to 15% acrylamide) and transfer to PVDF
(Immobilon, Millipore, Billerica, MA, USA), membranes were blocked with a protein-
free TBS blocking buffer (Pierce, Rockford, IL, USA) and gently agitated with
antibodies diluted in 5% non-fat dry milk or 5% BSA, as appropriate, at 41C
overnight. Secondary antibodies were from Amersham (Piscataway, NJ, USA).
Chemiluminescence was detected with the enhanced SuperSignal West
Pico Substrate (Pierce). The antibodies against Bcl-2 (#2872) and Bcl-XL (#2764)
were from Cell Signaling Technology (Beverly, MA, USA). The Mcl-1 (sc-819) anti-
body was from Santa Cruz Biotechnology (Santa Cruz, CA, USA), the Bim antibody
(#559685) was from BD Pharmingen (San Jose, CA, USA), and the Noxa anti-
bodywas fromCalbiochem(#OP180,SanDiego, CA,USA).Thea-tubulinantibody
(#T-6074) was from Sigma-Aldrich.
Proteasome activity assay. Proteasome activity in REN spheroids and
monolayers was measured using a commercial 20S proteasome activity assay kit
(APT280,MilliporeCorporation).Inbrief,spheroidsandmonolayerswerelysedwith
proteasomeactivitybuffer(50mMHEPES(pH7.5),5mMEDTA,150mMNaCland
1% Triton X-100). The lysates were incubated with the ﬂuorogenic substrate
LLVY-AMC, a ﬂuorophore 7-amino-4-methylcoumarin (AMC) bound with LLVY
peptide, at 371C for 2h. LLVY is a substrate recognized and cleaved by the 20S
proteasome. After LLVY chymotryptic cleavage by the 20S proteasome, AMC is
released and emits ﬂuorescence that can be read by using a 380nm excitation and
a 460nm emission ﬁlter in a ﬂuorometer.
RNA interference. Cells (4 10
6) were pelletedand resuspended in 100mlo f
nucleofectionbuffer(solutionT,AmaxaBiosystems,Cologne,Germany)with1.5mg
of the appropriate siRNA duplex (Ambion, Austin, TX, USA). A non-targeting siRNA
sequence was utilized as control in all experiments. This suspension was
transferred to a sterile cuvette and nucleofected using program T-20 on a
Nucleofector II device (Amaxa Biosystems). After 30-min recovery in complete
DMEM medium, the cells were plated and allowed to grow for 24h. Cells were then
trypsinized,countedandplatedasmonolayersandspheroidsfor24h,andexposed
to apoptotic stimuli. The siRNA sequences were: Bim (50-ACUUACAUCAGAAG
GUUGCtt-30), Mcl-1 (50-CCAGUAUACUUCUUAGAAAtt-30) and Noxa (50-GAAAU
GUGUCAAUAAUUACtt-30), non-targeting control (50-GCAACCUUCUGAUGUAA
GUtt-30).
BH3 proﬁling. Experiments were performed at the Dana Farber Cancer
Institute (Boston, MA, USA) by JA Ryan and AG Letai as previously published.
39
Monolayers and spheroids formed from equal numbers of cells were disaggregated
in an identical fashion to single cells. The cells were gently permeabilized as
described
39 and exposed to BH3 peptides (100mM) for 90min before JC1 was
added for 30min and depolarization measured as a percentage of the total.
Hoechst staining for measurement of apoptosis in multicellular
spheroids. Monolayers and spheroids were disaggregated by exposure to
trypsin for the same period of time, washed with ice-cold PBS, and then ﬁxed with
2.5% glutaraldehyde (Sigma-Aldrich). The cells were then stained with 8mg/ml of
Hoechst 33342 (Molecular Probes, Invitrogen, Carlsbad, CA, USA) and placed on
slides. For each condition, at least 300 cells were counted in triplicate by
investigators blinded to the experimental conditions. Cells with distinctive signs of
nuclear condensation were considered apoptotic.
Confocal analysis for measurement of apoptosis in TFS. In all,
5mm parafﬁn sections were deparafﬁnized with Xylene (2 5min), 100% EtOH
(2 2min), 95% EtOH (2 2min), 70% EtOH (2 2min), 50% EtOH (1 2min)
and ddH20 (2 2min). Endogenous peroxidases were blocked with a solution of
250mlMeOH þ 5ml 30%H202for20min.Antigenswereretrievedincitratebuffer
(Citra #HK087-5K, Biogenex, Fremont, CA, USA) in a microwave oven set to high
for7–8min.Sectionswereblockedwitha5%normalgoatserum,2.5%BSAinPBS
for30–45min inhumidiﬁed chamber atRT. Primary antibodies for cleavedcaspase 3
(1:100, #AB3623, Chemicon, Billerica, MA, USA) and pan-cytokeratin (1:100,
Progen, Heidelberg, Germany; clone GP14) were incubated in a humidiﬁed
chamberat 41C overnight.The secondaryantibodiesdonkeyanti-rabbitAlexaFluor
488 (Pierce; #31821) and anti-guinea pig AlexaFluor 633 (Invitrogen; #A-21105),
both 1:200, were incubated for 30–45min at RT in a humidiﬁed chamber. Slides
were washed three times in PBS for 3min and mounted with Vectashield. In a
blinded fashion, the investigators examined images of doubly stained slides.
Apoptotic mesothelioma cells were considered cells that had merged red (pan-
cytokeratin) and green (cleaved caspase 3) and were expressed as a percentage of
the total cells (DAPI-stained nuclei). For each condition, 3–10 spheroids were
counted until a total of 300 DAPI-stained cells were visualized.
Bim immunohistochemistry of TMAs. Two TMAs were studied. One
included the seven mesothelioma tumors that were studied as TFS for their
apoptotic response and two normal pleural samples. The second included 48
mesothelioma tumors and 5 normal pleural samples. All samples were obtained
without identiﬁers from surgeries performed at the Brigham and Women’s Hospital
and at UCSF Medical Center and were ﬁxed in formalin and assembled in a TMA.
Each sample was embedded in triplicate. The histopathology was determined on
separateformalin-ﬁxed,hematoxylin-andeosin-stainedsectionsofthetumor.Inall,
5mm parafﬁn sections of the TMA were processed as described for the confocal
analysis of apoptosis. Bim antibody (1:150, 41C overnight) was visualized with a
HRP/DAB Envisionþ Kit (Dako, Carpinteria, CA, USA; #K4010). Intensity of Bim
staining was measured by the Positive Pixel Count algorithm on a ScanscopeXT
system (Aperio Technologies, Inc., Vista, CA, USA), which determined the average
intensity of pixels within the tissue region of interest.
Statistical analysis. Data are expressed as mean±1 S.D. of at least three
different experiments. Statistical signiﬁcance was evaluated by one- or two-way
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Cell Death and Diseaseanalysis of variance, and Tukey’s test was performed to detect where the
differences lay (GraphPad Prism v 4.0, GraphPad Software, Inc., La Jolla, CA,
USA). A P-value o0.05 was considered signiﬁcant.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Acknowledgements. This work was supported by a TRDRP fellowship to DB
(18FT-0120),anIreland/NCIConsortiumgranttoVCB,DAFandDB(CDV/3679/07)
and a Department of Defense Mesothelioma Program grant to VCB and LMC
(PR080717).
1. Johnstone RW, Rueﬂi AA, Lowe SW. Apoptosis: a link between cancer genetics and
chemotherapy. Cell 2002; 108: 153–164.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
3. Smalley KS, Lioni M, Herlyn M. Life isn’t ﬂat: taking cancer biology to the next dimension.
In Vitro Cell Dev Biol Anim 2006; 42: 242–247.
4. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell
culture and live tissue. Nat Rev Mol Cell Biol 2007; 8: 839–845.
5. Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z et al. A novel
in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.
Am J Respir Cell Mol Biol 2005; 33: 541–548.
6. Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic
therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008; 5: 136–147.
7. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant
pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004;
5: 354–362.
8. Barbone D, Yang T, Morgan J, Gaudino G, Broaddus V. Mammalian target of rapamycin
contributes to the acquired apoptotic resistance of human mesothelioma multicellular
spheroids. J Biol Chem 2008; 283: 13021–13030.
9. Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, Renier A et al. Malignant
pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death
Differ 2009; 16: 1146–1155.
10. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D et al.
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo
activity in mesothelioma. Clin Cancer Res 2007; 13: 5942–5951.
11. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL et al. Preclinical
studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer
Chemother Pharmacol 2008; 61: 549–558.
12. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma.
Leukemia 2009; 23: 1964–1979.
13. Scagliotti GV, Germonpre P, Bosquee L, Vansteenkiste J, Gervais R, Planchard D et al.
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in
patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010;
68: 420–426.
14. Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor
bortezomib. Oncogene 2008; 27: 1189–1197.
15. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al.
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2
family members. Cancer Cell 2006; 9: 351–365.
16. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev
Cancer 2009; 9: 108–122.
17. Dalton WS. The proteasome. Semin Oncol 2004; 31(6 Suppl 16): 3–9; discussion 33.
18. Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H et al. Proteasome inhibitor
PS-341 induces apoptosis in cisplatin-resistantsquamous cell carcinoma cells by induction
of Noxa. J Biol Chem 2006; 281: 31440–31447.
19. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome
inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of
ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257–264.
20. Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND et al. ER stress
triggers apoptosis by activating BH3-only protein Bim. Cell 2007; 129: 1337–1349.
21. Futaki S. Oligoarginine vectors for intracellular delivery: design and cellular-uptake
mechanisms. Biopolymers 2006; 84: 241–249.
22. Kloss A, Henklein P, Siele D, Schmolke M, Apcher S, Kuehn L et al. The cell-penetrating
peptide octa-arginine is a potent inhibitor of proteasome activities. Eur J Pharm Biopharm
2009; 72: 219–225.
23. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3
mimetic ABT-737 targets selective Bcl-2 proteins and efﬁciently induces apoptosis via
Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389–399.
24. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells
that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304–3313.
25. BhatUG, PanditB, GartelAL.ARCsynergizes with ABT-737toinduce apoptosisinhuman
cancer cells. Mol Cancer Ther 2010; 9: 1688–1696.
26. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-
hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1
inactivation. J Natl Cancer Inst 2008; 100: 580–595.
27. Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine
sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 2009; 8:
883–892.
28. Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ et al. mTOR
mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
Am J Respir Cell Mol Biol 2008; 39: 576–583.
29. Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of
bortezomib-adapted I-45 mesothelioma cells. Mol Cancer 2010; 9: 110.
30. Han J, Goldstein LA, Hou W, Rabinowich H. Functional linkage between NOXA and Bim in
mitochondrial apoptotic events. J Biol Chem 2007; 282: 16223–16231.
31. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, Philippe M et al.
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by
bortezomib in multiple myeloma. Cancer Res 2007; 67: 5418–5424.
32. Woo HN, Seo YW, Moon AR, Jeong SY, Choi EK, Kim TH. Effects of the BH3-only protein
human Noxa on mitochondrial dynamics. FEBS Lett 2009; 583: 2349–2354.
33. Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R et al. Role of
NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic
lymphocytic leukemia cells. Haematologica 2010; 95: 1510–1518.
34. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307–315.
35. Yang TM, Barbone D, Fennell DA, Broaddus VC. Bcl-2 family proteins contribute to
apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 2009;
41: 14–23.
36. Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors
mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for
Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 2009; 29: 6149–6169.
37. Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P et al. Vorinostat synergistically
potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and
resistant to imatinib mesylate. Blood 2008; 112: 793–804.
38. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for
targeted cancer therapy. Cell Cycle 2009; 8: 3112–3119.
39. Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for
apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci USA 2010; 107:
12895–12900.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
DerivativeWorks3.0UnportedLicense. To view acopyof thislicense,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)
Bcl-2 blockade undermines multicellular resistance
D Barbone et al
9
Cell Death and Disease